(Total Views: 552)
Posted On: 05/30/2025 9:31:18 PM
Post# of 154003
Dec. letter:
"Entering 2025, the Company is in control of its own destiny."
"As previously announced, we are launching two preclinical studies in TNBC that will seek to further clarify the mechanism of action of leronlimab in oncology and identify potential treatment synergies to optimize the design of a follow-up clinical study."
Had data on 5/5 (100%) & ICI :
Ladies of Leronlimab
They were 6 months younger: 36, 40, 42, 46
Knew still needed follow-up confirmation.
But should now also be with FDA clarity.
Hired Dr. Tripathy who specializes in pre-salvage phases, 2 weeks after ESMO...think he was there &/or @ minimum in the loop?
Very common to collab months in advance.
Also from Dec.:
" We will continue to take one thoughtful step at a time to hit our milestones and, in turn, drive value for our shareholders. "
Steps to a partnership...is my bet
"Entering 2025, the Company is in control of its own destiny."
"As previously announced, we are launching two preclinical studies in TNBC that will seek to further clarify the mechanism of action of leronlimab in oncology and identify potential treatment synergies to optimize the design of a follow-up clinical study."
Had data on 5/5 (100%) & ICI :
Ladies of Leronlimab
They were 6 months younger: 36, 40, 42, 46
Knew still needed follow-up confirmation.
But should now also be with FDA clarity.
Hired Dr. Tripathy who specializes in pre-salvage phases, 2 weeks after ESMO...think he was there &/or @ minimum in the loop?
Very common to collab months in advance.
Also from Dec.:
" We will continue to take one thoughtful step at a time to hit our milestones and, in turn, drive value for our shareholders. "
Steps to a partnership...is my bet
(7)
(0)
